Cellectis SA (ALCLS)

Evaluation: Based on all recent filings, financial statements, and news.

See full evaluation
Company performance

Current Price

as of Jan 20, 2025

$1.56

P/E Ratio

N/A

Market Cap

$114.38M

Jan 30, 2024Mar 8, 2024Apr 10, 2024May 20, 2024Jun 21, 2024Jul 24, 2024Aug 27, 2024Oct 2, 2024Nov 4, 2024Dec 5, 2024Jan 20, 2025$0.00$10.00
  • PVT
Description

Cellectis SA operates as a clinical stage biotechnological company, which engages in gene-editing platform to develop cell and gene therapies. The company was founded by David J. Sourdive and André Choulika on February 20, 1999 and is headquartered in Paris, France.

Metrics

Overview

  • HQParis, IF
  • SectorHealth Technology
  • IndustryPharmaceuticals: Major
  • TickerALCLS
  • Price$1.560455-1.65%

Trading Information

  • Market cap$114.38M
  • Float71.42%
  • Average Daily Volume (1m)90,473
  • Average Daily Volume (3m)59,863
  • EPS-$0.95

Company

  • Revenue$26.67M
  • Rev growth (1yr)10,249.73%
  • Net income-$20.99M
  • Gross margin70.86%
  • EBITDA margin-49.85%
  • EBITDA-$7.35M
  • EV$60.83M
  • EV/Revenue2.28
  • P/EN/A
  • P/S5.68
  • P/B1.31
Documents